Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
PTX's Cash to Debt is ranked lower than
55% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. PTX: 0.05 )
PTX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.05

Equity to Asset 0.18
PTX's Equity to Asset is ranked lower than
52% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. PTX: 0.18 )
PTX' s 10-Year Equity to Asset Range
Min: 0.06   Max: 0.99
Current: 0.18

0.06
0.99
F-Score: 4
Z-Score: 0.32
M-Score: -2.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -65.74
PTX's Operating margin (%) is ranked higher than
52% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. PTX: -65.74 )
PTX' s 10-Year Operating margin (%) Range
Min: -64.4   Max: 38.22
Current: -65.74

-64.4
38.22
Net-margin (%) -36.68
PTX's Net-margin (%) is ranked higher than
53% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. PTX: -36.68 )
PTX' s 10-Year Net-margin (%) Range
Min: -91.07   Max: 33.08
Current: -36.68

-91.07
33.08
ROE (%) -34.55
PTX's ROE (%) is ranked higher than
53% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. PTX: -34.55 )
PTX' s 10-Year ROE (%) Range
Min: -42.27   Max: 137.29
Current: -34.55

-42.27
137.29
ROA (%) -11.64
PTX's ROA (%) is ranked higher than
56% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. PTX: -11.64 )
PTX' s 10-Year ROA (%) Range
Min: -12.35   Max: 68.03
Current: -11.64

-12.35
68.03
ROC (Joel Greenblatt) (%) -470.91
PTX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. PTX: -470.91 )
PTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -253.52   Max: 1552.82
Current: -470.91

-253.52
1552.82
Revenue Growth (3Y)(%) 17.90
PTX's Revenue Growth (3Y)(%) is ranked higher than
85% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. PTX: 17.90 )
PTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 107
Current: 17.9

0
107
» PTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

PTX Guru Trades in Q1 2013

Jim Simons 48,953 sh (-37.24%)
» More
Q2 2013

PTX Guru Trades in Q2 2013

Jim Simons Sold Out
» More
Q2 2014

PTX Guru Trades in Q2 2014

Jim Simons 157,637 sh (New)
» More
Q3 2014

PTX Guru Trades in Q3 2014

Jim Simons 100,837 sh (-36.03%)
» More
» Details

Insider Trades

Latest Guru Trades with PTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.12
PTX's P/B is ranked higher than
67% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. PTX: 4.12 )
PTX' s 10-Year P/B Range
Min: 0.26   Max: 14.61
Current: 4.12

0.26
14.61
P/S 3.95
PTX's P/S is ranked higher than
71% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. PTX: 3.95 )
PTX' s 10-Year P/S Range
Min: 0.07   Max: 8.78
Current: 3.95

0.07
8.78
EV-to-EBIT -10.88
PTX's EV-to-EBIT is ranked higher than
62% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. PTX: -10.88 )
PTX' s 10-Year EV-to-EBIT Range
Min: -163.1   Max: 280.5
Current: -10.88

-163.1
280.5
Current Ratio 1.23
PTX's Current Ratio is ranked higher than
54% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. PTX: 1.23 )
PTX' s 10-Year Current Ratio Range
Min: 0.84   Max: 64.5
Current: 1.23

0.84
64.5
Quick Ratio 1.10
PTX's Quick Ratio is ranked higher than
58% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. PTX: 1.10 )
PTX' s 10-Year Quick Ratio Range
Min: 0.62   Max: 64.5
Current: 1.1

0.62
64.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 12.70
PTX's Price/DCF (Projected) is ranked higher than
74% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.02 vs. PTX: 12.70 )
PTX' s 10-Year Price/DCF (Projected) Range
Min: 0.28   Max: 14.71
Current: 12.7

0.28
14.71
Price/Median PS Value 1.87
PTX's Price/Median PS Value is ranked higher than
60% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. PTX: 1.87 )
PTX' s 10-Year Price/Median PS Value Range
Min: 0.05   Max: 4.2
Current: 1.87

0.05
4.2
Earnings Yield (Greenblatt) -9.20
PTX's Earnings Yield (Greenblatt) is ranked higher than
52% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. PTX: -9.20 )
PTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 16.7
Current: -9.2

0.4
16.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:GTAP.Germany,
Pernix Therapeutics Holdings Inc were incorporated in Maryland in November 1996. The Company is a specialty pharmaceutical company that sells, markets, manufactures and develops a number of branded and generic pharmaceutical products primarily indicated for sleep, bacterial infections and cough and cold conditions. The Company branded products includes CEDAX, an antibiotic for middle ear infections, and a family of prescription treatments for cough and cold. The Company also market SILENOR (doxepin), which is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. The Company also currently promotes Omeclamox-Pak through a License and Supply Agreement with GastroEntero-Logic, LLC; as entered into a promotion agreement with Cumberland Pharmaceuticals pursuant to which Cumberland began promoting Omeclamox-Pak to gastroenterologists. The Company also entered into an Exclusive License Agreement with Osmotica Pharmaceutical Corp. to promote its desvenlafaxine product, Khedezla Extended-Release Tablets, 50 and 100 mg. It sells its generic products in the areas of cough and cold, pain, vitamins, dermatology, antibiotics and gastroenterology through its wholly-owned subsidiaries. The Companys branded product portfolio includes; SILENOR; KHEDEZLA; CEDAX; ZUTRIPRO; REZIRA; VITUZ; and OMECLAMOX-PAK. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Companys product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.
» More Articles for PTX

Headlines

Articles On GuruFocus.com
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Nov 12 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Aug 16 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Pernix Therapeutics Inc. to Present at the Oppenheimer Healthcare Conference in New York, NY Dec 01 2014
Pernix Therapeutics Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Financials Nov 22 2014
Pernix Submits sNDA for TREXIMET® Use in Adolescent Patients Nov 17 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial... Nov 10 2014
Pernix Therapeutics Reports Third Quarter 2014 Financial Results and Reaffirms Guidance Nov 10 2014
Pernix Therapeutics to Report Q3 2014 Financial Results Oct 27 2014
3 Stocks Under $10 Making Big Moves Higher Oct 15 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits Oct 09 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Oct 09 2014
4 Stocks Under $10 Triggering Breakout Trades Oct 03 2014
5 Breakout Stocks Under $10 Set to Soar Sep 26 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 22 2014
Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014... Aug 20 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2014
Pernix Therapeutics Reports Second Quarter 2014 Financial Results Aug 11 2014
Closing for Pernix Transaction to Acquire Treximet® Tablets for Migraine from GSK Delayed Aug 04 2014
Pernix Therapeutics to Report Second Quarter 2014 Financial Results on August 11, 2014 Jul 25 2014
Gyrotron Technology Inc. Elects Jan H. Loeb to Its Board of Directors Jul 22 2014
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK